OnKure Therapeutics to Present Preliminary Data From PIKture-01 Trial of OKI-219 at SABCS 2024
OnKure Therapeutics to Present Preliminary Data From PIKture-01 Trial of OKI-219 at SABCS 2024
The investor call will be held on Tuesday, December 10, 2024, at 7:00 a.m. CT (8:00 a.m. ET).OnKure Therapeutics will present preliminary data from the OKI-219 trial at SABCS on December 12, 2024.
OnKure Therapeutics将于2024年12月12日在SABCS上展示OKI-219试验的初步数据。
Quiver AI Summary
Quiver AI 概要
OnKure Therapeutics, Inc. has announced that selected posters, including preliminary data from their PIKture-01 trial of OKI-219, will be presented at the upcoming 2024 San Antonio Breast Cancer Symposium (SABCS). Key details of the trial, which focuses on a mutant-selective inhibitor for advanced solid tumors, will be discussed in an investor call scheduled for December 10, 2024, at 7:00 a.m. CT, moving from the previously planned date of December 13. The posters will showcase findings related to OKI-219's effectiveness, with presentations on December 12. OnKure's ongoing research aims to develop targeted therapies for cancer, with OKI-219 as a lead candidate, highlighting their commitment to addressing underserved cancer types. Further details and updates will be made available on their website following the symposium.
OnKure Therapeutics, Inc.宣布将在即将举行的2024年圣安东尼奥乳腺癌研讨会(SABCS)上展示包括他们的PIKture-01试验关于OKI-219的初步数据在内的精选海报。该试验重点研究用于治疗先进实体瘤的突变选择性抑制剂，在定于2024年12月10日上午7点在Ct的投资者电话会议中将讨论关于试验的关键细节，比原定日期提前至12月13日。海报将展示有关OKI-219有效性的研究结果，相关演讲将于12月12日举行。OnKure正在积极开展研究，旨在开发针对癌症的靶向疗法，OKI-219作为主要候选药物，突显了他们解决未被满足的癌症类型方面的承诺。随后将在研讨会结束后在他们的网站上公布更多细节和更新。
Potential Positives
潜在的积极因素
- OnKure Therapeutics is presenting preliminary data from its first-in-human PIKture-01 trial of OKI-219 at the prestigious San Antonio Breast Cancer Symposium, highlighting its innovative approach in oncology.
- The company is holding an investor call to review this new data, indicating its commitment to transparency and investor engagement.
- OKI-219 is positioned as a potentially significant treatment option for advanced solid tumors, which could enhance OnKure's profile in the biopharmaceutical industry.
- The poster presentations will include additional data on the efficacy of OKI-219 with standard of care therapies in mutant breast cancer models, suggesting promising research outcomes.
- OnKure Therapeutics正在在备受尊敬的圣安东尼奥乳腺癌研讨会上展示其先进的PIKture-01试验初步数据，突显其在肿瘤学领域的创新方法。
- 公司将举行投资者电话会议，审查这些新数据，表明了其对透明度和投资者参与的承诺。
- OKI-219被定位为先进实体瘤的潜在重要治疗选择，这有望提升OnKure在生物制药行业的声誉。
- 海报展示将包括有关OKI-219与突变乳腺癌模型中标准治疗方法的有效性的更多数据，暗示着有望取得良好的研究成果。
Potential Negatives
潜在负面影响
- Changing the date of the investor call from December 13 to December 10 may indicate urgency or concern regarding the preliminary data, which could raise questions about the robustness of the findings.
- The need to publish preliminary data from the clinical trial could suggest that definitive results have not yet been achieved, potentially undermining investor confidence.
- Investors may view the reliance on forward-looking statements as a sign of risk and uncertainty regarding the company's future prospects and the development of their product candidates.
- 将投资者看涨日期从12月13日改为12月10日，可能表明对初步数据的紧急性或关注，这可能引发对研究结果的稳健性提出质疑。
- 需要发布来自临床试验的初步数据可能表明尚未取得明确结果，可能削弱投资者的信心。
- 投资者可能认为依赖前瞻性声明显示了对公司未来前景和产品候选品开发的风险和不确定性。
FAQ
FAQ
What is OnKure Therapeutics announcing?
OnKure Therapeutics正在宣布什么?
OnKure is announcing poster presentations and an investor call regarding the preliminary data from the PIKture-01 trial of OKI-219.
OnKure宣布海报展示和投资者看涨会议，涉及PIKture-01试验OKI-219的初步数据
When will the investor call take place?
投资者看涨会议何时举行?
The investor call will be held on Tuesday, December 10, 2024, at 7:00 a.m. CT (8:00 a.m. ET).
投资者电话会议将于2024年12月10日星期二上午7:00在Ct (东部时间上午8:00)举行。
How can I access the presentation of the PIKture-01 trial?
我如何查看PIKture-01试验的演示？
The presentation can be accessed through a conference call or webcast available on OnKure's website.
演示可通过OnKure网站上提供的电话会议或网络直播访问。
What is the focus of the PIKture-01 clinical trial?
PIKture-01临床试验的重点是什么？
The PIKture-01 trial focuses on OKI-219 as a treatment for advanced solid tumors and advanced breast cancer.
PIKture-01试验的重点是将OKI-219作为晚期实体肿瘤和晚期乳腺癌的治疗。
Where can I find more information about OnKure and its projects?
我在哪里可以找到关于OnKure及其项目的更多信息？
More information about OnKure and its ongoing projects can be found on their official website at .
有关OnKure及其正在进行的项目的更多信息，请访问官方网站。
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
免责声明：这是由GlobeNewswire分发的新闻稿的人工智能生成摘要。用于总结这份稿件的模型可能会出错。请在这里查看完整发布。
Full Release
全面发布
BOULDER, Colo., Nov. 25, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that posters selected for presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS), including the poster presenting the preliminary data from the Company's first-in-human PIKture-01 trial of OKI-219, will be published to the symposium's virtual meeting platform for registered attendees on December 10
th
.
OnKure Therapeutics公司(NASDAQ: OKUR)是一家专注于肿瘤学领域新型精准药物开发的临床阶段生物制药公司，今天宣布将在2024年12月10日举行的2024年圣安东尼奥乳腺癌研讨会(SABCS)上发布入选展示的海报，包括展示公司首个人体试验OKI-219的PIKture-01试验初步数据的海报，将发布到研讨会的虚拟会议平台供注册参会者查看。
楼
.
OnKure will now hold its investor call to review preliminary data from the PIKture-01 study of OKI-219 on Tuesday, December 10, 2024 at 7:00 a.m. CT (8:00 a.m. ET). The Company had previously announced the investor call would be held on Friday, December 13, 2024. To join the call, please dial 877-407-0789 (domestic), 201-689-8562 (international) and refer to conference ID 13750009. The call may also be accessed via webcast (
click here
) or from the Events page of the Investors section of the Company's website at
. A replay of the webcast will be available on OnKure's website for at least 30 days following the call.
OnKure现在将于2024年12月10日上午7:00（中部时间）（东部时间上午8:00）举行投资者电话会议，审查OKI-219的PIKture-01研究的初步数据。公司此前宣布投资者电话会议将于2024年12月13日星期五举行。请拨打877-407-0789（国内），201-689-8562（国际），并提及会议ID 13750009参加电话会议。也可以通过网络广播（
点击这里
）或公司网站投资者部分的活动页面上访问该电话会议。OnKure的网站将提供电话会议后至少30天的网络广播回放。
在电话会议后，OnKure的网站将提供至少30天的网络广播回放。
In addition, today, SABCS published the full text from all regular abstracts on its website (
click here
). OnKure plans to include additional data in the posters being presented at SABCS, which will be made available on the Company's website after the poster is presented.
此外，今天，SABCS在其网站上发布了所有常规摘要的全文（
点击这里
）。OnKure计划在SABCS展示的海报中包含额外数据，在海报展示后将在公司网站上提供。
There are no changes to the planned in-person poster presentations at SABCS, which is taking place in San Antonio, Texas.
计划中的现场海报展示在SABCS中不会有任何变化，该会议将在德克萨斯州圣安东尼奥举行。
Poster presentation details:
Poster Title:
Preliminary results from PIKture-01, a First-in-Human Study of OKI-219, a mutant
selective inhibitor of PI3Kα
H1047R
, in mutant selected solid tumors including breast cancer
Author:
Alexander Spira, MD, PhD, et al.
Presentation ID:
P3-08-19
Poster Session:
Poster Session 3
Session Location:
Halls 2-3
Presentation Date/Time:
Thursday, December 12, 2024 12:30 PM to 2:00 PM CST
Abstract Number:
SESS-3634
海报展示详情：
海报标题:
来自PIKture-01的初步结果，这是一项关于OKI-219的首个人体研究，这是一种突变
PI3Kα的选择性抑制剂
H1047R"
在突变选择的实体肿瘤中，包括乳腺癌
作者：
Alexander Spira, MD, PhD等
演示标识：
P3-08-19
海报展示会：
海报展示第3场
会议地点:
2-3号展厅
演讲日期/时间：
2024年12月12日 星期四 下午12:30 至 下午2:00 中部时间
摘要编号：
SESS-3634
Poster Title:
OKI-219 enhances activity of SOC therapies in double and triple combinations in pre-clinical PI3Kα
H1047R
mutant breast cancer models
Author:
Molly Taylor, PhD, et al.
Presentation ID:
P4-12-20
Poster Session:
Poster Session 4
Session Location:
Halls 2-3
Presentation Date/Time:
Thursday, December 12, 2024 05:30 PM to 7:00 PM CST
Abstract Number:
SESS-2240
海报标题:
OKI-219增强了SOC疗法在临床前PI3Kα双和三联疗法中的活性
H1047R"
突变乳腺癌模型
作者：
Molly Taylor博士等
演讲编号：
P4-12-20
海报展示会：
海报展示会议4
会议地点:
2-3号厅
演讲日期/时间:
2024年12月12日星期四 下午05:30至07:00 中部标准时间
摘要编号：
SESS-2240
For more details about SABCS please visit:
.
有关SABCS的更多详细信息，请访问:
.
OKI-219 is being investigated in the PIKture-01 clinical trial. PIKture-01 is a first-in-human study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as monotherapy in participants with advanced solid tumors and in combination with endocrine therapy or HER2-Targeted Therapy in participants with advanced breast cancer. Additional information about PIKture-01 may be found at
, using Identifier: NCT06239467.
OKI-219正在进行PIKture-01临床试验。 PIKture-01是关于PI3KαH1047R Mutant-Selective Inhibitor OKI-219首个人类研究，用于对抗晚期实体瘤的患者，以及与内分泌治疗或HER2靶向治疗联合应用于晚期乳腺癌患者。关于PIKture-01的更多信息可在以下找到
，使用标识符：NCT06239467。
About OnKure
关于OnKure
OnKure is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using structure-based drug design platform, OnKure is building a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability. OnKure is currently developing OKI-219, a selective PI3Kα
H1047R
inhibitor, as its lead program. OnKure aims to become a leader in targeting oncogenic PI3Kα and has multiple programs designed to enable best-in-class targeting of this key oncogene.
OnKure是一家临床阶段的生物制药公司，专注于发现和开发针对癌症生物学验证的驱动因子的最佳精准药物，而这些癌症目前缺乏有效治疗方案。利用基于结构的药物设计平台，OnKure正在建立一系列针对肿瘤不可知性的候选药物，旨在实现最佳功效和耐受性。OnKure目前正在开发OKI-219，一种选择性PI3Kα抑制剂作为其主导项目。OnKure旨在成为针对致癌PI3Kα的领先者，并拥有多个旨在实现最佳级别靶向治疗这一关键致癌基因的项目。
H1047R"
有关OnKure的更多信息，请访问我们的网站，在LinkedIn上关注我们。
For more information about OnKure, visit us at
and follow us on LinkedIn.
有关更多OnKure信息，请访问我们的网站
，并在LinkedIn上关注我们。
Forward-Looking Statements
前瞻性声明
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for future operations, as well as statements regarding industry trends, are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of, and expectations regarding, OnKure's product candidates and programs, including OKI-219; OnKure's ability to advance additional programs; the expected milestones and timing of such milestones, including for OKI-219 and its discovery programs; and statements regarding OnKure's financial position, including its liquidity, cash runway and the sufficiency of its cash resources. In some cases, you can identify forward-looking statements by terminology such as "estimate," "intend," "may," "plan," "potentially" "will" or the negative of these terms or other similar expressions.
本新闻稿包含涉及重大风险和不确定性的前瞻性声明。本新闻稿中除了历史事实声明之外的所有声明，包括关于我们未来财务状况、经营业绩、业务策略和计划以及管理层未来业务目标的声明，以及关于行业趋势的声明，都属于前瞻性声明。这些前瞻性声明包括但不限于，关于OnKure的产品候选药物和计划，包括OKI-219的潜力和预期；OnKure推进额外项目的能力；对这些里程碑以及OKI-219及其发现项目的预期里程碑和时间的声明；以及关于OnKure财务状况，包括其流动性、现金储备和现金资源充足性的声明。在某些情况下，您可以通过类似“估计”、“打算”、“可能”、“计划”、“潜在”、“将”或这些术语的否定形式或其他类似表达方式，识别前瞻性声明。
The company based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things, those risks described in the section entitled "Risk Factors" in documents that OnKure files from time to time with the Securities and Exchange Commission ("SEC"), including the final 424B3 proxy statement/prospectus filed with the SEC on August 26, 2024. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this press release.
该公司主要基于我们对未来事件和趋势的当前期望和预测制定这些前瞻性声明，我们认为这些事件和趋势可能影响我们的财务状况、经营业绩、业务策略和财务需求。这些前瞻性声明受到许多风险、不确定性和假设的影响，包括在OnKure不时向证券交易委员会（“SEC”）提交的文件中如《风险因素》一节所描述的风险，包括OnKure于2024年8月26日向SEC提交的最终424B3代理声明/招股书中描述的风险。这些风险并非详尽无遗。新的风险因素不时出现，我们的管理团队无法预测所有风险因素，也无法评估所有因素对我们业务的影响或任何因素或多个因素可能导致实际结果与任何前瞻性声明中包含的结果有实质差异，或被暗中指示。您不应依赖前瞻性声明作为未来事件的预测。尽管我们认为前瞻性声明所反映的期望是合理的，但我们无法保证未来的结果、活动水平、表现或成就。除非法律要求，我们不承诺在本新闻稿发布日期后出于任何原因公开更新任何前瞻性声明。
Contact:
联系方式：
Dan Ferry
LifeSci Advisors
daniel@lifesciadvisors.com
丹·费里，电话：(617) 430-7576
LifeSci顾问
daniel@lifesciadvisors.com
